From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2016 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“必须说服买家考虑”转变为“已获批准、指定、列入、合格、注册、报销或预先授权”的买家自身采购、报销、处方集、规格、采购、网络、目录或计划系统中的选择,从而使得公司未来业务的很大一部分可以在没有每次单独销售事件的情况下到达,并且管理层是否传达了这种准入状态是新的,以至于它所带来的大部分交易量仍领先于已报告的结果。 在记录中,管理层讨论了各种业务更新,包括租赁、最低工资、各地区表现、佛罗里达州下降、拉斯维加斯建设、纽约强劲、华盛顿特区、大西洋城、波士顿、康涅狄格、佛罗里达、以及 Meadowlands 赛马场投资。关于 Meadowlands,他们提到新泽西州立法机构允许在11月进行公投,以允许在该州北部进行赌场赌博。他们拥有11.6%的权益,并拥有四家餐厅和所有食品服务的独家经营权(除了硬石咖啡厅)。然而,这仍是待定的,公投尚未通过,因此不是已批准的状态。他们正在开展营销活动以帮助解释为什么这是好事,但尚未获得批准。因此,这不符合“已批准、指定、列入”等条件,而是“待定、申请中、希望中”或取决于尚未获得的批准。 没有提到公司被列入任何买家系统、处方集、供应商名单等。管理层讨论的是普通业务运营、销售趋势和投资机会。没有描述公司从候选者转变为默认选择的具体系统。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.